Search results for ''
Founders
ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership and scientific excellence in biology and drug development to bring the company forward.
Company overview
Our mission
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.
The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Roughly 30-50% of NASH patients have CKD through common bidirectional pathways leading to severe renal impairment.
Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.
Latest Press Release 